Boehringer Ingelheim, Drug Prices & Medicare Spending

Boehringer Ingelheim manufactures 15 drugs tracked by Medicare Part D with total spending of $8.5B.

Drugs Tracked

$8.5B

Medicare Spending

$99.77

Avg Cost/Claim

100%

Have Generics

Boehringer Ingelheim Drugs, Ranked by Medicare Spending

#	Drug	Generic Name	Cost/Claim	Medicare Spending	YoY Change	Generic?
1	Jardiance	Empagliflozin	$210.00	$3.9B	+22.7%	Yes
2	Spiriva	Tiotropium	$146.00	$912.0M	-8.9%	Yes
3	Pradaxa	Dabigatran	$180.00	$876.0M	-9.8%	Yes
4	Synjardy	Empagliflozin/Metformin	$175.00	$567.0M	+14.2%	Yes
5	Tradjenta	Linagliptin	$134.00	$567.0M	-4.2%	Yes
6	Stiolto Respimat	Tiotropium/Olodaterol	$189.00	$234.0M	-6.8%	Yes
7	Empagliflozin	Empagliflozin	$48.00	$234.0M	+14.6%	Yes
8	Glyxambi	Empagliflozin/Linagliptin	$189.00	$234.0M	+4.6%	Yes
9	Aggrenox	Aspirin/Dipyridamole	$72.00	$178.0M	-22.4%	Yes
10	Jentadueto	Linagliptin/Metformin	$144.00	$178.0M	-4.8%	Yes
11	Tamsulosin	Tamsulosin Hydrochloride	$8.00	$123.0M	-24.6%	Yes
12	Pramipexole	Pramipexole Dihydrochloride	$50.00	$123.0M	-18.4%	Yes
13	Gilotrif	Afatinib	$8,786.00	$123.0M	-18.6%	Yes
14	Meloxicam	Meloxicam	$6.00	$89.0M	-22.4%	Yes
15	Telmisartan	Telmisartan	$18.00	$89.0M	-14.2%	Yes

Frequently Asked Questions

Boehringer Ingelheim manufactures 15 drugs tracked by Medicare Part D, with total annual spending of $8.5B.

Gilotrif (Afatinib) is the most expensive at $8,786.00 per claim.

15 of 15 Boehringer Ingelheim drugs (100%) have generic alternatives available. Generic drugs can save patients 30-80% compared to brand-name versions.

this entity is one of the data points covered by this site’s U.S. Medicare prescription-drug pricing dataset. The detail above comes directly from CMS Medicare Part D Drug Spending data; the context that follows situates the headline numbers against the broader distribution across U.S. prescription drugs.

The methodology behind every numeric value on this page is publicly documented on the CMS Medicare Part D Drug Spending data portal and described in detail on this site’s methodology page. Refresh cadence varies by underlying series; the page surfaces the as-of date for each number so readers can trace any figure back to the source release.

Practical use of this page is in combination with the comparison and ranking pages elsewhere on the site, which surface the same data for this entity’s peers within U.S. prescription drugs. A single-entity reading without peer context can be misleading when an entity is an outlier on one axis but typical on another.

Source: CMS Medicare Part D Spending, 2026.